<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3B1E5961-8677-4A32-B15C-12FB968FA163"><gtr:id>3B1E5961-8677-4A32-B15C-12FB968FA163</gtr:id><gtr:name>University of Pennsylvania</gtr:name><gtr:address><gtr:line1>3451 Walnut Street,</gtr:line1><gtr:line2>Suite P-221</gtr:line2><gtr:line3>Franklin Building</gtr:line3><gtr:line4>Philadelphia</gtr:line4><gtr:postCode>PA 19104</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E34F39A1-E98F-45E3-A8AF-57F7D0B7A942"><gtr:id>E34F39A1-E98F-45E3-A8AF-57F7D0B7A942</gtr:id><gtr:name>Necker-Enfants Malades Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FCD90BB9-BD1C-43D4-98EE-AE74283911E3"><gtr:id>FCD90BB9-BD1C-43D4-98EE-AE74283911E3</gtr:id><gtr:name>Free University of Brussels (ULB)</gtr:name><gtr:address><gtr:line1>Avenue Franklin Roosevelt 50</gtr:line1><gtr:postCode>B-1050</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8B42480C-C16B-45BD-A61E-FCB97FD77B2C"><gtr:id>8B42480C-C16B-45BD-A61E-FCB97FD77B2C</gtr:id><gtr:name>RIKEN</gtr:name><gtr:address><gtr:line1>1-7-22, Suehiro-cho</gtr:line1><gtr:line2>Tsurumi-ku</gtr:line2><gtr:line4>Yokohama</gtr:line4><gtr:line5>Kanagawa 230-0045</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Sir William Dunn Sch of Pathology</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3B1E5961-8677-4A32-B15C-12FB968FA163"><gtr:id>3B1E5961-8677-4A32-B15C-12FB968FA163</gtr:id><gtr:name>University of Pennsylvania</gtr:name><gtr:address><gtr:line1>3451 Walnut Street,</gtr:line1><gtr:line2>Suite P-221</gtr:line2><gtr:line3>Franklin Building</gtr:line3><gtr:line4>Philadelphia</gtr:line4><gtr:postCode>PA 19104</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E34F39A1-E98F-45E3-A8AF-57F7D0B7A942"><gtr:id>E34F39A1-E98F-45E3-A8AF-57F7D0B7A942</gtr:id><gtr:name>Necker-Enfants Malades Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FCD90BB9-BD1C-43D4-98EE-AE74283911E3"><gtr:id>FCD90BB9-BD1C-43D4-98EE-AE74283911E3</gtr:id><gtr:name>Free University of Brussels (ULB)</gtr:name><gtr:address><gtr:line1>Avenue Franklin Roosevelt 50</gtr:line1><gtr:postCode>B-1050</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8B42480C-C16B-45BD-A61E-FCB97FD77B2C"><gtr:id>8B42480C-C16B-45BD-A61E-FCB97FD77B2C</gtr:id><gtr:name>RIKEN</gtr:name><gtr:address><gtr:line1>1-7-22, Suehiro-cho</gtr:line1><gtr:line2>Tsurumi-ku</gtr:line2><gtr:line4>Yokohama</gtr:line4><gtr:line5>Kanagawa 230-0045</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/13FD1EF0-BFFC-4E6A-871F-AB23CEA96DCE"><gtr:id>13FD1EF0-BFFC-4E6A-871F-AB23CEA96DCE</gtr:id><gtr:firstName>Herman</gtr:firstName><gtr:surname>Waldmann</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/54A99119-BFC7-485F-82CB-E6CD0FCB4399"><gtr:id>54A99119-BFC7-485F-82CB-E6CD0FCB4399</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>P</gtr:otherNames><gtr:surname>Cobbold</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G7904009"><gtr:id>6C521A51-6A4F-4677-AB24-1AEAA2DDB19E</gtr:id><gtr:title>Therapeutic Immunoregulation.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G7904009</gtr:grantReference><gtr:abstractText>We will establish the rules by which the mouse immune system can be made to tolerate transplants without long-term immunosuppressive drugs. The main emphasis will be to characterise a special set of lymphocytes (regulatory T cells) that act to prevent transplant rejection and to establish ways by which they can be selectively primed by the graft. We will use transgenic mice that express a uniform receptor committed to just one transplantation antigen, so eliminating the ?noise? from the vast majority of irrelevant lymphocytes from the analysis. These mice, and T cell clones and lines derived from them, will be used to follow the cell biology and key signalling mechanisms of these regulatory T cells. This information should lead to improved strategies to achieve tolerance in clinical transplantation, and to re-establish it in autoimmune disease.

We have exhibited at Royal Society soirees and exhibitions, and have given lay lectures on ?reprogramming? and therapeutic antibodies to the Royal Institution and to school parties visiting Oxford. We maintain an active website http://www.molbiol.ox.ac.uk/pathology/tig/welcome.html that lays out our research activities.</gtr:abstractText><gtr:technicalSummary>We have discovered that short courses of CD4 antibody therapy can enable tolerance to foreign proteins, transplanted tissues, and can restore tolerance in autoimmunity. In the absence of blood chimerism, transplantation tolerance requires the induction and participation of CD4+ regulatory T cells. This programme seeks to fulfil a number of objectives. 
1) To evolve improved antibody-based strategies for induction of transplantation tolerance directed to the organ itself, and to the combination of organ and marrow stem cells.
2) To identify critical molecules that enable dendritic cells to tolerise T cells and polarise them towards regulatory function. 
3) To identify the mechanisms by which regulatory T cells can suppress graft rejection. 
We will exploit a number of resources that have already been established in this laboratory including TCR transgenic (A1.RAG-/-) mice whose CD4+ T cells have specificity for a single minor transplantation antigen - the male peptide Dby; technology for differentiating genetically transduced ES cells to become immature and matured dendritic cells; and a large database of SAGE libraries to provide a baseline for assigning relationships between cells and for identifying genes that are differentially expressed between cell populations. 
The TCR transgenic mice will provide populations of monospecific T cells subjected to tolerising protocols within the TCR transgenic host, or within mice with a normal replete immune system, or in vitro. We will investigate the cell and molecular requirements of the inductive and effector processes exploited by regulatory T cells, and how these are integrated into the immune system as a whole. 
This information should lead to improved strategies to achieve tolerance in clinical transplantation, and to re-establish it in autoimmune disease.</gtr:technicalSummary><gtr:fund><gtr:end>2010-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1980-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>8387139</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>RIKEN</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>creation of a reporter mouse for tracking regulatory T-cells</gtr:description><gtr:id>36E9242A-EA87-4AFD-B4C9-27E736E66AE2</gtr:id><gtr:impact>16304635</gtr:impact><gtr:outcomeId>20857A07189-1</gtr:outcomeId><gtr:partnerContribution>This collaboration has enabled us to track and ablate regulatory T-cells in-vivo,opening up many hitherto refractory avenues of research.</gtr:partnerContribution><gtr:piContribution>I had the concept,and created the gene construct. Shohei Hori had the knock-in mouse made in the transgenic facility at the Riken</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Free University of Brussels</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>Academic Phase II trial in human type I diabetes</gtr:description><gtr:id>F078779C-E1F7-4E2B-813E-7672C9F7B6BD</gtr:id><gtr:impact>Phase III trials are now in progress by Tolerx and GSK using our antibody but with modified prot0cols. our work was published in the New England Journal. 15972866</gtr:impact><gtr:outcomeId>AD21FB94DCB-1</gtr:outcomeId><gtr:partnerContribution>We have shown that short term therapy can give long-term reversal of Type I diabetes, validating many of the concepts that started with our work on using antibodies to induce tolerance in the mid-1980s.</gtr:partnerContribution><gtr:piContribution>We engineered the anti-CD3 antibody, manufactured it and di a great deal of preclinical testing and safety testing in the 1990s. The European consortium performed the clinical trial under the leadership of Prof Lucienne Chatenoud and Prof Daniel Pipeleers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Pennsylvania</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Crystal structure of the mouse GITRL</gtr:description><gtr:id>5467CB99-C07F-4667-BEC7-E4C0F9DEF8FB</gtr:id><gtr:impact>PNAS publication. 18178614</gtr:impact><gtr:outcomeId>CFED8CBB237-1</gtr:outcomeId><gtr:partnerContribution>Has suggested possible ways GITRL may bind to its receptor, and making some predictions of different biological outcomes</gtr:partnerContribution><gtr:piContribution>We cloned and expressed the gene, Prof Mark Greene purified the protein and did the crystallograpphy</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Necker-Enfants Malades Hospital</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>GITRL antibodies as therapeutics for Type I diabetes</gtr:description><gtr:id>A28A3F06-FCAB-486F-A260-0F706FBF72B5</gtr:id><gtr:impact>PLOS publication. 19936238</gtr:impact><gtr:outcomeId>C99E63A9A6A-1</gtr:outcomeId><gtr:partnerContribution>We made rat monoclonal antibodies to GITRL, and conceived the idea of using them as short term therapeutics to reverse autoimmune diabetes. We collaborated with Lucienne Chatenoud an expert in murine diabetes, and showed that anti-GITR antibodies exacerbate, while anti-GITRL antibodies reverse disease.</gtr:partnerContribution><gtr:piContribution>We made the anti-GITRL antibodies used in this study, and conceived the idea that they may be useful therapeutics.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Clinical Medicine</gtr:department><gtr:description>A novel treatment for relapsing-remitting multiple sclerosis</gtr:description><gtr:id>923E43E3-F275-4714-83E5-667C59D368BD</gtr:id><gtr:impact>Genzyme is now conducting Phase III studies, and there is every chance that this will become a licensed drug for multiple sclerosis. 16044212</gtr:impact><gtr:outcomeId>261F6C566CF-1</gtr:outcomeId><gtr:partnerContribution>We have been evaluating our antibody CAMPATH-1H in multiple sclerosis with this group since 1991. With antibody we manufactured in Oxford. CAMPATH1H has a long lasting beneficial effect in relapsing-remitting disease.A recent collaboration shows that the immunogenicity of the therapeutic antibody can be further reduced by pretolersing patients wit a non-cell-binding muitant of CAMPATH-1H</gtr:partnerContribution><gtr:piContribution>We developed and manufactured the therapeutic antibody used. We have supplied it to Prof A Compston since 1991, and with him and his colleagues evolved the protocols for treatment.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Murray Society,Lincoln college alumni</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>232A6D82-DB23-4D3D-8BAD-AFB747B26328</gtr:id><gtr:impact>Mostly--describing our short term therapies for long-term benefit to the media.

Tolerance is becoming a much more &amp;quot;popular&amp;quot; target for therapeutic strategies.I am sure we have had an influence.</gtr:impact><gtr:outcomeId>B52565BC846</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Framework 7 Beta cell Therapy</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>224A5EFC-D908-475D-84D7-B8CE01D69186</gtr:id><gtr:outcomeId>FBC0D3DAD300</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Hmanisation serquence of therapeutic anti-CD3 antibody</gtr:description><gtr:grantRef>G7904009</gtr:grantRef><gtr:id>16DAB165-41EA-4F27-81C2-D52039563CF0</gtr:id><gtr:impact>In trials</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>naL7M8rkJn2</gtr:outcomeId><gtr:patentId>US2007092516</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Humanized anti-CD3 specific antibodies</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>short-term treatment benefits multiple sclerosis</gtr:description><gtr:grantRef>G7904009</gtr:grantRef><gtr:id>729A8921-A732-4CD9-BD4E-10538AFBB340</gtr:id><gtr:impact>Successful Phase III study . Will be sold as Lemtrada.
Predicted to be most efficacious treatment for MS</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>GmhZjxD1ZHc</gtr:outcomeId><gtr:patentId>US2005118172</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>6120766 CDW52-specific antibody for treatment of multiple sclerosis</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>CD3 antibodies as short term treatments for inflammatory arthritides (such as rheumatoid arthritis)</gtr:description><gtr:grantRef>G7904009</gtr:grantRef><gtr:id>307E8CD8-864F-4070-B514-E6BD009D7547</gtr:id><gtr:impact>Trials have been accomplished in Type I diabetes but wrong doses chosen by GSK. Future trials in planning</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>fguZ3duKzUr</gtr:outcomeId><gtr:patentId>US7993641</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Methods of treatment using anti-CD3 antibodies</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Engineered antibodies to reduce immunogenicity</gtr:description><gtr:grantRef>G7904009</gtr:grantRef><gtr:id>8B00B7DA-2C81-4BAE-B930-C1C726B0555A</gtr:id><gtr:impact>n/a</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>PfZj6rQakFf</gtr:outcomeId><gtr:patentId>WO2010023482</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Therapeutic antibodies</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>protection of antibodies to CD52</gtr:description><gtr:grantRef>G7904009</gtr:grantRef><gtr:id>466EECCC-E9B6-49BD-8AB3-EE32DA4423D3</gtr:id><gtr:impact>part of poatent package for Alemtuzumab/Lemtrada-a licensed drug</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>bmsQ8fV3DFF</gtr:outcomeId><gtr:patentId>US6569430</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Antibodies to the antigen Campath-1</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>short term use of CD4 antibody to tolerise the immune system to foreign proteins</gtr:description><gtr:grantRef>G7904009</gtr:grantRef><gtr:id>547485A5-5B92-4507-BBEE-B21F83E04F0B</gtr:id><gtr:impact>Yes-fundamental discoveries on how the immune system regulates itself.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>U8g2ShcunPt</gtr:outcomeId><gtr:patentId>WO2004067554</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Compositions and methods of tolerizing a primate to an antigen</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Humanised anti-human CD4 antibody for therapy</gtr:description><gtr:grantRef>G7904009</gtr:grantRef><gtr:id>F8DB2FD6-1204-4ACB-B37F-C8D10F56A372</gtr:id><gtr:impact>n/a</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>skwSmb43Wpq</gtr:outcomeId><gtr:patentId>US7541443</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Anti-CD4 antibodies</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A novel way to eliminate antibody immunogenicity and treatment side-effects</gtr:description><gtr:grantRef>G7904009</gtr:grantRef><gtr:id>FD4EF434-20FE-4001-BBB5-9CAFFCC9429B</gtr:id><gtr:impact>n/a</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>BuxdwLnYfL2</gtr:outcomeId><gtr:patentId>US6767996</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Altered antibodies and their preparation</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>therapeutic antibodies</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>D8CA8D5B-3FDC-4F9B-9A1E-6FF32D03A9C9</gtr:id><gtr:impact>application of immunology to treatment</gtr:impact><gtr:outcomeId>SrUAHAxQNCT</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>anti-CD3 therapy for Type I diabetes. A non-lytic antibody that interrupts development of islet cell destruction, and given as a short term treatment preserves some islet cell mass long term.Should minimize long-term complications and management of diabetes</gtr:description><gtr:id>BF5AF680-3306-47AA-9C36-F961AA1F3A80</gtr:id><gtr:impact>This is an example of a tolerising therapy that can reprogramme the immune system for therapeutic benefit. here fulfilling an unmet medical need.</gtr:impact><gtr:outcomeId>8CD6B8133B0</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Otelixizumab  (anti-CD3)</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>antibodies to human IL7R for possible therapeutic development</gtr:description><gtr:id>F9900559-2BEC-4B60-A8DD-67FB5E867870</gtr:id><gtr:impact>awaiting commercial interest</gtr:impact><gtr:outcomeId>LZiaA3bxQqz</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>anti-IL7R</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>mice lacking these genes for study of function</gtr:description><gtr:id>D41A49A0-224C-4494-A8BC-C499BDB0CC5A</gtr:id><gtr:impact>use of these mouse models to study metabolic influences on immune regulation</gtr:impact><gtr:outcomeId>T9gYTG45Agp</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>knockout mice for b-cat1, GITRL, and CD73</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A human cDNA encoding a humanmarker (CD2) was knocked into the mouse FoxP3 locus. Any regulatory T-cellexpressing FoxP3 can be identified by expression of CD2 on ghe cell membrane</gtr:description><gtr:id>B43716C3-D9CA-4E3B-AE69-4C31033C18DB</gtr:id><gtr:impact>Anew way to ablate regulatory T-cells in-vivo. Will greatly aid research in this field.</gtr:impact><gtr:outcomeId>F50529454F6</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>A strain of mouse to track regulatory T-cells</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>new monoclonal antibodies to defined subpopulations of white cells.</gtr:description><gtr:id>7E47E9EA-1D2E-4F17-B729-CB6CD9ACB6D5</gtr:id><gtr:impact>Catalysed research</gtr:impact><gtr:outcomeId>69164A7965D</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>monoclonal antibodies  to GITR and GITRL</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We used Serial analysis of Gene expression tofollow genes expressed in defined cell types.We have made that database public.</gtr:description><gtr:id>5DE661CF-DE4A-4E31-AD2A-E3206C913267</gtr:id><gtr:impact>Hard to evaluate this.</gtr:impact><gtr:outcomeId>B9DB915CF3F</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>SAGEgene database</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Monoclonal antibodies</gtr:description><gtr:id>FBB5B43B-F32E-499E-872F-9269780DC6E2</gtr:id><gtr:impact>enhance research activities of other groups</gtr:impact><gtr:outcomeId>QjGVkf2k9oJ</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>antibodies to PDL1, CD73, LAG3, CD103</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C25C7CC6-2A02-41A6-AA24-1A2FB1C509EC</gtr:id><gtr:title>Special regulatory T cell review: The suppression problem!</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d0f3b566b3dd22bba4cd03cf55c23ee"><gtr:id>2d0f3b566b3dd22bba4cd03cf55c23ee</gtr:id><gtr:otherNames>Waldmann H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>C41E9D7AC5D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05DA44E9-2A2E-4DB5-8F60-16981AA20221</gtr:id><gtr:title>Infectious tolerance and the long-term acceptance of transplanted tissue.</gtr:title><gtr:parentPublicationTitle>Immunological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d0f3b566b3dd22bba4cd03cf55c23ee"><gtr:id>2d0f3b566b3dd22bba4cd03cf55c23ee</gtr:id><gtr:otherNames>Waldmann H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0105-2896</gtr:issn><gtr:outcomeId>9C0DD5AA677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB8421E5-ECDF-4988-8906-9FAA8B0B5636</gtr:id><gtr:title>Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc2989d8a6a7f2763a931f788f0f6f9a"><gtr:id>cc2989d8a6a7f2763a931f788f0f6f9a</gtr:id><gtr:otherNames>CAMMS223 Trial Investigators</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>6CE0B1BBB64</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CADE453A-7539-4EEA-B3C9-93ED5ED6D1C6</gtr:id><gtr:title>Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/812f154025ba9e104b45caa81cbccb93"><gtr:id>812f154025ba9e104b45caa81cbccb93</gtr:id><gtr:otherNames>Tuyaerts S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>8BE0F1FC007</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45F86C3E-6B31-49A7-8E5E-8EB82585B3E3</gtr:id><gtr:title>A key role for TGF-beta signaling to T cells in the long-term acceptance of allografts.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24f343f94f2b76d8a0804d1ffc045151"><gtr:id>24f343f94f2b76d8a0804d1ffc045151</gtr:id><gtr:otherNames>Daley SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>52642D7C8E2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83023CEB-504D-4D68-9F2D-5883E7F268D7</gtr:id><gtr:title>Key role of the GITR/GITRLigand pathway in the development of murine autoimmune diabetes: a potential therapeutic target.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aaa89a4d32207044f172cc3f143af73f"><gtr:id>aaa89a4d32207044f172cc3f143af73f</gtr:id><gtr:otherNames>You S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>B2F5DDE669B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E3623ED-592C-453A-8CD2-6AED5D0DD6BB</gtr:id><gtr:title>MS4A4B is a GITR-associated membrane adapter, expressed by regulatory T cells, which modulates T cell activation.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ee12a2614ed8a1358b7add17f976e24"><gtr:id>0ee12a2614ed8a1358b7add17f976e24</gtr:id><gtr:otherNames>Howie D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>8D5E4F87A8B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72A53F89-9A9C-4D02-A01D-EE3D3B41B658</gtr:id><gtr:title>Generation of anti-inflammatory adenosine by leukocytes is regulated by TGF-?.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/900e4a7bc9765800a9634035381a53ef"><gtr:id>900e4a7bc9765800a9634035381a53ef</gtr:id><gtr:otherNames>Regateiro FS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>B4TtmsYQyQe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94AD2C88-A44B-408B-BB67-E4AF71D746F7</gtr:id><gtr:title>Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c9ee0469e4235765d6d620108426297"><gtr:id>7c9ee0469e4235765d6d620108426297</gtr:id><gtr:otherNames>Robertson NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5166E67D7A9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0465C43-AA12-4D4F-8334-42143C385B9E</gtr:id><gtr:title>Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c0a3f7104e99d6b0ef932aa9cd225ee"><gtr:id>7c0a3f7104e99d6b0ef932aa9cd225ee</gtr:id><gtr:otherNames>Glatting G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>13BEBCBC317</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A52491A-753F-41F1-B95A-CA2EB3BA0858</gtr:id><gtr:title>Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52a1d1beb632601883aa10f819a277a0"><gtr:id>52a1d1beb632601883aa10f819a277a0</gtr:id><gtr:otherNames>Lorenzi AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn><gtr:outcomeId>568145B7E5A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34E03DB6-EB77-4162-BF65-50FA0FA38AC1</gtr:id><gtr:title>Tolerance can be infectious.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d0f3b566b3dd22bba4cd03cf55c23ee"><gtr:id>2d0f3b566b3dd22bba4cd03cf55c23ee</gtr:id><gtr:otherNames>Waldmann H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>29C21CF2E89</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C19BA87D-BE3F-4480-A233-4E5E7DBBCF52</gtr:id><gtr:title>Regulatory T cells: context matters.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d0f3b566b3dd22bba4cd03cf55c23ee"><gtr:id>2d0f3b566b3dd22bba4cd03cf55c23ee</gtr:id><gtr:otherNames>Waldmann H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>279419411BD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F17A0D0-F12F-47E2-BBDD-62BE15271D45</gtr:id><gtr:title>Regulatory T cells and transplantation tolerance.</gtr:title><gtr:parentPublicationTitle>Immunotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbd8650137b3c0ff0e77db52f6d5c3d5"><gtr:id>bbd8650137b3c0ff0e77db52f6d5c3d5</gtr:id><gtr:otherNames>Hilbrands R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1750-743X</gtr:issn><gtr:outcomeId>pm_14770_20_23829623</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26860C7B-CCA0-4E75-8D65-6019039A126F</gtr:id><gtr:title>Secreted and transmembrane 1A is a novel co-stimulatory ligand.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ee12a2614ed8a1358b7add17f976e24"><gtr:id>0ee12a2614ed8a1358b7add17f976e24</gtr:id><gtr:otherNames>Howie D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14770_20_24039998</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D879D76B-BD0D-432B-AD51-FA32D0F7495B</gtr:id><gtr:title>Immunology: protection and privilege.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d0f3b566b3dd22bba4cd03cf55c23ee"><gtr:id>2d0f3b566b3dd22bba4cd03cf55c23ee</gtr:id><gtr:otherNames>Waldmann H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>pmvM24ZSPXB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87AE1CBF-EFB7-4B48-A077-32EDB420516C</gtr:id><gtr:title>The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3af9933a303fbce09c355116aa956ae0"><gtr:id>3af9933a303fbce09c355116aa956ae0</gtr:id><gtr:otherNames>Coles AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>DD7065181E8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E978F8E3-9E51-412B-8F43-C1D32D514BC6</gtr:id><gtr:title>The Induction and Maintenance of Transplant Tolerance Engages Both Regulatory and Anergic CD4T cells.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5c46e35c88b22df756168abc1900544"><gtr:id>b5c46e35c88b22df756168abc1900544</gtr:id><gtr:otherNames>Besan?on A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a9fbedf00ea89.91511725</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49A4C8FE-777B-45B5-9FA1-AA8B9B355F6B</gtr:id><gtr:title>Fc-disabled anti-mouse CD40L antibodies retain efficacy in promoting transplantation tolerance.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24f343f94f2b76d8a0804d1ffc045151"><gtr:id>24f343f94f2b76d8a0804d1ffc045151</gtr:id><gtr:otherNames>Daley SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>211198BEDF2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DB2E049-9ED2-4259-BA82-B0C131053765</gtr:id><gtr:title>A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/651fac6d12b0eee894ae396d3b2efcf9"><gtr:id>651fac6d12b0eee894ae396d3b2efcf9</gtr:id><gtr:otherNames>Morgan AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>594A90CA261</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC6C44C5-E6D9-4EA2-92DC-8D2963853C10</gtr:id><gtr:title>Regulatory T cells in transplantation.</gtr:title><gtr:parentPublicationTitle>Seminars in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d0f3b566b3dd22bba4cd03cf55c23ee"><gtr:id>2d0f3b566b3dd22bba4cd03cf55c23ee</gtr:id><gtr:otherNames>Waldmann H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1044-5323</gtr:issn><gtr:outcomeId>ENazoTvrE1R</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6BE749A-6D14-4F8E-9C28-A71E26FBBB2E</gtr:id><gtr:title>Regulatory cells and transplantation tolerance.</gtr:title><gtr:parentPublicationTitle>Cold Spring Harbor perspectives in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffceb12522ddfcc1b45e3dd4aa6349eb"><gtr:id>ffceb12522ddfcc1b45e3dd4aa6349eb</gtr:id><gtr:otherNames>Cobbold SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2157-1422</gtr:issn><gtr:outcomeId>pm_14770_20_23732858</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52978216-B827-49DB-B269-F4DD6C1C9865</gtr:id><gtr:title>Human monoclonal antibodies: the residual challenge of antibody immunogenicity.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d0f3b566b3dd22bba4cd03cf55c23ee"><gtr:id>2d0f3b566b3dd22bba4cd03cf55c23ee</gtr:id><gtr:otherNames>Waldmann H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>pm_14770_20_24037833</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D20EDC1-827D-48C5-9617-BE3475D33B2C</gtr:id><gtr:title>Activation rather than Foxp3 expression determines that TGF-?-induced regulatory T cells out-compete na&amp;iuml;ve T cells in dendritic cell clustering.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aabb4a3c08d22654d635504cdccd286f"><gtr:id>aabb4a3c08d22654d635504cdccd286f</gtr:id><gtr:otherNames>Chen Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_14770_20_22678900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8785A33D-00D0-4F6A-8A51-4616A0E9D90B</gtr:id><gtr:title>Embryonic stem cells: overcoming the immunological barriers to cell replacement therapy.</gtr:title><gtr:parentPublicationTitle>Current stem cell research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/760d02a5d76154f04677d338e441b556"><gtr:id>760d02a5d76154f04677d338e441b556</gtr:id><gtr:otherNames>Lui KO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1574-888X</gtr:issn><gtr:outcomeId>E134A6EE3AA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41EB6030-2904-4622-B201-A9344446F447</gtr:id><gtr:title>Structural basis for ligand-mediated mouse GITR activation.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bf1ecd4c4c7b837a4d6237fe9fed466"><gtr:id>2bf1ecd4c4c7b837a4d6237fe9fed466</gtr:id><gtr:otherNames>Zhou Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>651E300EBF3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77347207-F220-420F-B2F1-0EF44FFB2936</gtr:id><gtr:title>Mechanisms of antibody immunotherapy on clonal islet reactive T cells.</gtr:title><gtr:parentPublicationTitle>Human immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae9eb9aab46a7e9accdd49d13875214a"><gtr:id>ae9eb9aab46a7e9accdd49d13875214a</gtr:id><gtr:otherNames>van de Linde P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0198-8859</gtr:issn><gtr:outcomeId>YWJmqkLmVwD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BF9ECBA-FCAB-4376-AB91-FEB721A06928</gtr:id><gtr:title>Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning.</gtr:title><gtr:parentPublicationTitle>BMC immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55cb81482fca6addc32b937c7fb498ce"><gtr:id>55cb81482fca6addc32b937c7fb498ce</gtr:id><gtr:otherNames>Graca L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1471-2172</gtr:issn><gtr:outcomeId>142FFE71A9F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29DE36EF-9E46-4648-92BF-0B1B762383FD</gtr:id><gtr:title>Regulation and privilege in transplantation tolerance.</gtr:title><gtr:parentPublicationTitle>Journal of clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d0f3b566b3dd22bba4cd03cf55c23ee"><gtr:id>2d0f3b566b3dd22bba4cd03cf55c23ee</gtr:id><gtr:otherNames>Waldmann H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0271-9142</gtr:issn><gtr:outcomeId>B7DAEC43E42</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3926A989-4DD1-4435-A4D5-356CFD5D905F</gtr:id><gtr:title>Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4aa2cafd71498c626b9a9c9820a583e"><gtr:id>c4aa2cafd71498c626b9a9c9820a583e</gtr:id><gtr:otherNames>Clatworthy MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>3123428CD65</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D37C999-C0F0-431B-87E0-CC4C2680560E</gtr:id><gtr:title>Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3ef100a03d16c193319f59e37ddb7de"><gtr:id>d3ef100a03d16c193319f59e37ddb7de</gtr:id><gtr:otherNames>Komatsu N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>1F09D673940</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>774682C0-3EAB-484F-9156-ACB6CFB646E8</gtr:id><gtr:title>Foxp3 expression is required for the induction of therapeutic tissue tolerance.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/900e4a7bc9765800a9634035381a53ef"><gtr:id>900e4a7bc9765800a9634035381a53ef</gtr:id><gtr:otherNames>Regateiro FS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_14770_20_22988034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F5CA4FE-A902-4DAF-A993-9C8D8D78BEB5</gtr:id><gtr:title>Immune privilege induced by regulatory T cells in transplantation tolerance.</gtr:title><gtr:parentPublicationTitle>Immunological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffceb12522ddfcc1b45e3dd4aa6349eb"><gtr:id>ffceb12522ddfcc1b45e3dd4aa6349eb</gtr:id><gtr:otherNames>Cobbold SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0105-2896</gtr:issn><gtr:outcomeId>2EC768A013F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4663FA1-04F9-4C78-BB3E-133FCBFA1D72</gtr:id><gtr:title>Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46dcd3ee5d402ca900cb3dddad794cda"><gtr:id>46dcd3ee5d402ca900cb3dddad794cda</gtr:id><gtr:otherNames>Neujahr DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>QwmaigJL5SC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFAF538D-FC46-4873-8E81-0D14526AB8F5</gtr:id><gtr:title>Infectious tolerance via the consumption of essential amino acids and mTOR signaling.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffceb12522ddfcc1b45e3dd4aa6349eb"><gtr:id>ffceb12522ddfcc1b45e3dd4aa6349eb</gtr:id><gtr:otherNames>Cobbold SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>D0E88672903</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B87BAA55-EFFE-40DF-AFE0-5E2D5C85B77A</gtr:id><gtr:title>Reprogramming the immune system using antibodies.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55cb81482fca6addc32b937c7fb498ce"><gtr:id>55cb81482fca6addc32b937c7fb498ce</gtr:id><gtr:otherNames>Graca L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>7A1DBDABE82</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE5B987C-0E8D-4651-8A08-C73D57ABC771</gtr:id><gtr:title>A novel role for Glucocorticoid-Induced TNF Receptor Ligand (Gitrl) in early embryonic zebrafish development.</gtr:title><gtr:parentPublicationTitle>The International journal of developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c41d2bf9a341063b77248da8e2ea40a"><gtr:id>7c41d2bf9a341063b77248da8e2ea40a</gtr:id><gtr:otherNames>Poulton LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0214-6282</gtr:issn><gtr:outcomeId>B343EC1FC34</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BBB313A-64C3-4EE6-80A9-0B86700E8162</gtr:id><gtr:title>Tolerogenicity is not an absolute property of a dendritic cell.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2eb04a0ddbd30b517dbc08a9fee2f213"><gtr:id>2eb04a0ddbd30b517dbc08a9fee2f213</gtr:id><gtr:otherNames>Farquhar CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_14770_20_20373289</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74FD91A0-D241-4FF2-B96B-B9DA7C87F587</gtr:id><gtr:title>SAGE analysis of cell types involved in tolerance induction.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db5d08b4af53565072fc99b44a491f78"><gtr:id>db5d08b4af53565072fc99b44a491f78</gtr:id><gtr:otherNames>Nolan KF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>C3074B253B0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBD7BEE0-C23E-482A-8ABD-40C7F4A58BE0</gtr:id><gtr:title>Induction of regulatory T cells and dominant tolerance by dendritic cells incapable of full activation.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aad47ac13f2362b1f5cf818ca4c17946"><gtr:id>aad47ac13f2362b1f5cf818ca4c17946</gtr:id><gtr:otherNames>Yates SF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>0A05826BB25</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22CD78C6-8DD1-42FC-84F0-2890C5A1DDE8</gtr:id><gtr:title>CD8+ T-Cell depletion and rapamycin synergize with combined coreceptor/stimulation blockade to induce robust limb allograft tolerance in mice.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a4e3979f177e6ad9e72d3a5c818988a"><gtr:id>5a4e3979f177e6ad9e72d3a5c818988a</gtr:id><gtr:otherNames>Li Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>58522391BD5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>909A20E1-F540-4AA1-A765-21706E0208E3</gtr:id><gtr:title>Genetic modification of dendritic cells through the directed differentiation of embryonic stem cells.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9aabd38d22ef90645151cece851cdb1b"><gtr:id>9aabd38d22ef90645151cece851cdb1b</gtr:id><gtr:otherNames>Fairchild PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>362B0A602B7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A377D370-D38D-4861-B3C3-384895B3E556</gtr:id><gtr:title>Reprogramming the immune system: co-receptor blockade as a paradigm for harnessing tolerance mechanisms.</gtr:title><gtr:parentPublicationTitle>Immunological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d0f3b566b3dd22bba4cd03cf55c23ee"><gtr:id>2d0f3b566b3dd22bba4cd03cf55c23ee</gtr:id><gtr:otherNames>Waldmann H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0105-2896</gtr:issn><gtr:outcomeId>515CF442D6D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6F3A958-66B2-484F-8DE5-E36593227281</gtr:id><gtr:title>Reprogramming the immune system.</gtr:title><gtr:parentPublicationTitle>Clinical transplants</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d0f3b566b3dd22bba4cd03cf55c23ee"><gtr:id>2d0f3b566b3dd22bba4cd03cf55c23ee</gtr:id><gtr:otherNames>Waldmann H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0890-9016</gtr:issn><gtr:outcomeId>44F2A4DFBB5</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G7904009</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>78E3B265-B307-4D06-9AB7-1F69471E721F</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.4  Surgery</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>